Format

Send to

Choose Destination
FEBS J. 2013 May;280(10):2294-306. doi: 10.1111/febs.12168. Epub 2013 Mar 4.

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

Author information

1
Department of Pathology, University of Alabama at Birmingham, AL 35294, USA.

Abstract

Heparanase is an endoglucuronidase that cleaves heparan sulfate chains of proteoglycans. In many malignancies, high heparanase expression and activity correlate with an aggressive tumour phenotype. A major consequence of heparanase action in cancer is a robust up-regulation of growth factor expression and increased shedding of syndecan-1 (a transmembrane heparan sulfate proteoglycan). Substantial evidence indicates that heparanase and syndecan-1 work together to drive growth factor signalling and regulate cell behaviours that enhance tumour growth, dissemination, angiogenesis and osteolysis. Preclinical and clinical studies have demonstrated that therapies targeting the heparanase/syndecan-1 axis hold promise for blocking the aggressive behaviour of cancer.

PMID:
23374281
PMCID:
PMC3651779
DOI:
10.1111/febs.12168
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center